Warning: fopen(/home/virtual/colon/journal/upload/ip_log/ip_log_2025-11.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Ann Coloproctol > Volume 31(3); 2015 > Article
Editorial
 ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
Moo-Jun Baek
Annals of Coloproctology 2015;31(3):81-81.
DOI: https://doi.org/10.3393/ac.2015.31.3.81
Published online: June 30, 2015

Department of Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.

Correspondence to: Moo-Jun Baek, M.D. Department of Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 330-930, Korea. Tel: +82-41-570-3633, Fax: +82-41-571-0129, ssurge@sch.ac.kr

© 2015 The Korean Society of Coloproctology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 3,494 Views
  • 32 Download
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus
Full Article

Download PDF Download PDF

See Article on Page [Related article:] 92-97
Oxaliplatin is known to be a platinum-based chemotherapeutic agent that carries a 1, 2-diamino-cyclohexane ring. This drug has shown in vitro and in vivo antitumor activities in patients with colorectal cancer (CRC) [1]. The addition of oxaliplatin to 5FU (FOLFOX regimen) was shown to improve the adjuvant treatment of stage-III colon cancer by reducing the risk of recurrence and increasing overall survival [23]. Oxaliplatin exerts its action by forming DNA-platinum mono-adducts, primarily with guanines. Oxaliplatin also inhibits DNA replication and transcription and induces apoptosis [1]. Generally, oxaliplatin-induced adducts are not recognized by the mismatch repair system, but are repaired by the nucleotide excision repair and base excision repair pathways [45]. An enhanced DNA repair efficiency may contribute to a resistance to platinum-based cytotoxic drugs. Several studies have demonstrated that single nucleotide polymorphisms involved in DNA repair, such as excision repair cross-complementing group 1 (ERCC1) [6], may predict the clinical outcome for patients receiving oxaliplatin-based chemotherapy for the treatment of CRC. In metastatic CRC, measurements of the ERCC1 and the thymidylate synthase (TS) expressions have potential clinical utility in managing patients, and several studies have addressed the role of ERCC1 in terms of adjuvant colon-cancer treatment.
The authors used immunohistochemical staining in an attempt to identify ERCC1 as a predictive marker for FOLFOX adjuvant chemotherapy in treating patients with stage-II and -III colon cancer [7]. They found that ERCC1 expression was not significantly correlated with the 5-year disease-free survival as reflected by the oncologic outcomes in patients with high-risk stage-II and -III colon cancer treated with FOLFOX adjuvant chemotherapy. Although the authors could not show any predictive impact of ERCC1, negative results regarding ERCC1 in the era of colon cancer are not unusual, which is the reason a further prospective, large-scale study is needed regarding this issue.

CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported.

  • 1. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053–1071. ArticlePubMed
  • 2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351. ArticlePubMed
  • 3. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198–2204. ArticlePubMed
  • 4. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3–11. ArticlePubMed
  • 5. Zaanan A, Meunier K, Sangar F, Flejou JF, Praz F. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol (Dordr) 2011;34:155–176. ArticlePubMed
  • 6. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011;17:1632–1640. ArticlePubMedPMC
  • 7. Kim CY, Seo SH, An MS, Kim KH, Hwang JW, Kim JH, et al. ERCC1 as a predictive marker for FOLFOX chemotherapy in an adjuvant setting. Ann Coloproctol 2015;31:92–97.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy
      Aziza E. Abdelrahman, Doaa Abdelaziz Ibrahim, Ahmed El-Azony, Ahmed A. Alnagar, Amr Ibrahim
      Cancer Biomarkers.2020; 27(2): 251.     CrossRef

    • Cite this Article
      Cite this Article
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
      Ann Coloproctol. 2015;31(3):81-81.   Published online June 30, 2015
      DOI: https://doi.org/10.3393/ac.2015.31.3.81
      Close
    • XML DownloadXML Download
    ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    Ann Coloproctol : Annals of Coloproctology Twitter Facebook
    © Korean Society of Coloproctology.
    TOP